Aligos Therapeutics (ALGS)
Develops liver- and viral-disease drug candidates, including a chronic hepatitis B program.
Something off on this page? Send us feedback.
Develops drug candidates for liver and viral diseases, including a Phase 2 chronic hepatitis B program. The clinical-stage company has no product-sales revenue and relies on financing and license or collaboration payments to fund its pipeline.
Develops drug candidates for liver and viral diseases, including a chronic hepatitis B program evaluating pevifoscorvir sodium in a Phase 2 trial.
Founded in 2018, it has been led by co-founder Lawrence M. Blatt since formation and became a Nasdaq-listed company in 2020. Based in South San Francisco, it remains clinical-stage and reports no product-sales revenue. Research and development are supported by equity financing, license payments and collaborations.
An exclusive-license arrangement gives Xiamen Amoytop Biotech Greater China development and commercialization rights for pevifoscorvir sodium. Clinical development, financing and collaboration or licensing proceeds are central operating dependencies.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 21, 2026 | Cantor Fitzgerald | Target | Target: — | Target: $20 |
| Jan 7, 2026 | UBS | Target | Target: — | Target: $20 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $30.4M · Total debt $3.5M · Total assets $66.3M · Shareholders' equity $31.9M
- Revenue
- $27.8M
- Operating income
- −$1.9M
- Net income
- −$1.5M
No dividends on record.
| Institutions | 55.07% | 6.88M shares | |
|---|---|---|---|
| 31 holders · as of Jun 30, 2026 | |||
| Other | 44.93% | 5.61M shares | |
| remainder | |||
12.49M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (12.49M in the company's Sep 22, 2026 report, 6.19M elsewhere); stakes use the report.
This company has 3 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Deep Track Capital, LPInstitution | 10.67% | 444,110 · 444,110 · 444,110 | as of Jun 30, 2026 |
Alyeska Investment Group, L.P.Institution | 9.90% | 412,000 · 412,000 · 412,000 | as of Jun 30, 2026 |
Sio Capital Management, LLCInstitution | 7.86% | 327,237 · 327,237 · 327,237 | as of Jun 30, 2026 |
Marshall Wace, LLPInstitution | 5.92% | 246,579 · 246,579 · 246,579 | as of Jun 30, 2026 |
Woodline Partners LPInstitution | 4.26% | 177,362 · 177,362 · 177,362 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- GSK (ADR)
Regulatory-stage chronic-HBV functional-cure challenger
- Gilead Sciences
Chronic-HBV treatment benchmark through marketed Vemlidy
- Arbutus Biopharma
Functional-cure chronic-HBV programs with RNAi and PD-L1 inhibition
- Assembly Biosciences
Oral HBV capsid-modulator program awaiting a development partner
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aligos Therapeutics | $6.05 | +10.20% | $34.0M | — | — | 1.1 | +2,778.6% |
| GSK (ADR) | $50.66 | −0.82% | $102.34B | 16.1 | 9.3 | 2.3 | +5.3% |
| Gilead Sciences | $150.71 | +0.10% | $186.93B | — | 16.6 | 6.1 | +10.2% |
| Arbutus Biopharma | $5.01 | +0.16% | $987.7M | 6.4 | — | 5.4 | −90.6% |
| Assembly Biosciences | $25.49 | +0.21% | $504.2M | 46.3 | — | 6.7 | +38.9% |
| Median | 16.1 | 12.9 | 5.8 | +7.8% |